ARWR Key Statistics, Chart & Performance
The current stock price of ARWR is 52.7 USD. In the past month the price increased by 43.24%. In the past year, price increased by 121.71%.
ARWR Latest News, Press Relases and Analysis
ARWR Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.1 | 402.25B | ||
| AMGN | AMGEN INC | 15.8 | 185.98B | ||
| GILD | GILEAD SCIENCES INC | 15.37 | 156.14B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.98 | 111.17B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.33 | 82.69B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 884.76 | 59.15B | ||
| INSM | INSMED INC | N/A | 43.92B | ||
| NTRA | NATERA INC | N/A | 32.78B | ||
| BIIB | BIOGEN INC | 10.88 | 26.70B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.42 | 21.98B | ||
| INCY | INCYTE CORP | 16.27 | 20.40B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.18B |
Related stock screener links
About ARWR
Company Profile
Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The company is headquartered in Pasadena, California and currently employs 609 full-time employees. The firm's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. The firm's Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. The company is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, muscle and central nervous system. The company has around 16 clinical-stage investigational medicines (wholly owned and partnered), which range in development stage from Phase I to Phase III. The firm's pipeline products include Plozasiran, Zodasiran, Olpasiran, ARO-RAGE, ARO-MMP7, GSK-4532990, Fazirsiran, GSK5637608, ARO-CFB, ARO-INHBE, ARO-C3, ARO-PNPLA3, ARO-DUX4, ARO-DM1 and ARO-ATXN2.
Company Info
ARROWHEAD PHARMACEUTICALS IN
177 E Colorado Blvd, Suite 700
Pasadena CALIFORNIA 91105 US
CEO: Christopher Anzalone
Employees: 609
Phone: 16266964702
ARROWHEAD PHARMACEUTICALS IN / ARWR FAQ
What does ARWR do?
Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The company is headquartered in Pasadena, California and currently employs 609 full-time employees. The firm's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. The firm's Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. The company is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, muscle and central nervous system. The company has around 16 clinical-stage investigational medicines (wholly owned and partnered), which range in development stage from Phase I to Phase III. The firm's pipeline products include Plozasiran, Zodasiran, Olpasiran, ARO-RAGE, ARO-MMP7, GSK-4532990, Fazirsiran, GSK5637608, ARO-CFB, ARO-INHBE, ARO-C3, ARO-PNPLA3, ARO-DUX4, ARO-DM1 and ARO-ATXN2.
Can you provide the latest stock price for ARROWHEAD PHARMACEUTICALS IN?
The current stock price of ARWR is 52.7 USD. The price decreased by -8.68% in the last trading session.
Does ARWR stock pay dividends?
ARWR does not pay a dividend.
How is the ChartMill rating for ARROWHEAD PHARMACEUTICALS IN?
ARWR has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Should I buy ARWR stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on ARWR.
What is the next earnings date for ARWR stock?
ARROWHEAD PHARMACEUTICALS IN (ARWR) will report earnings on 2026-02-09.
ARWR Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to ARWR. When comparing the yearly performance of all stocks, ARWR is one of the better performing stocks in the market, outperforming 98.16% of all stocks.
ARWR Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ARWR. The financial health of ARWR is average, but there are quite some concerns on its profitability.
ARWR Financial Highlights
Over the last trailing twelve months ARWR reported a non-GAAP Earnings per Share(EPS) of -0.08. The EPS increased by 98.4% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -10.78% | ||
| ROE | -28.5% | ||
| Debt/Equity | 1.07 |
ARWR Forecast & Estimates
20 analysts have analysed ARWR and the average price target is 50.53 USD. This implies a price decrease of -4.12% is expected in the next year compared to the current price of 52.7.
For the next year, analysts expect an EPS growth of -3334.16% and a revenue growth -44.48% for ARWR